2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
3
Breast Neoplasms
3
Sarcoma, Synovial
2
Recurrence
2
Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Lymphoma
2
Liposarcoma, Myxoid
2
Hodgkin Disease
2
Graft vs Host Disease
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Nervous System Diseases
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Interventions
Temozolomide
131
Radiotherapy
87
Bevacizumab
43
Radiation
31
Carmustine
29
Magnetic Resonance Spectroscopy
22
Irinotecan
22
Erlotinib Hydrochloride
22
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gene Expression Profiling
7
Gefitinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Interferon-gamma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled